IL2 and plasma cell myeloma: Wilhelm and colleagues (9) were the first to demonstrate that activation of Vγ9Vδ2 T cells with pamidronate and low-dose interleukin 2 (IL-2) could induce clinical responses in patients with B-cell lymphomas and multiple myeloma (MM).